Attenuation of the Niemann-Pick type C2 disease phenotype by intracisternal administration of an AAVrh.10 vector expressing Npc2

Sandra Markmann, Jasmine J. Christie-Reid, Jonathan B. Rosenberg, Bishnu P. De, Stephen M. Kaminsky, Ronald Crystal, Dolan Sondhi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Niemann-Pick type C2 (NPC2) disease is a rare, neurodegenerative disorder caused by mutations in the NPC2 gene, leading to lysosomal accumulation of unesterified cholesterol and other lipids. It is characterized by hepatosplenomegaly, liver dysfunction and severe neurological manifestations, resulting in early death. There is no effective therapy for NPC2 disease. Here, we evaluated the effectiveness of an adeno-associated virus (AAV), serotype rh.10 gene transfer vector expressing the mouse Npc2 gene (AAVrh.10-mNpc2-HA, HA tagged to facilitate analysis) to treat the disease in an Npc2−/− mouse model. A single intracisternal administration of the AAVrh.10-mNpc2-HA to 6 week old Npc2−/− mice mediated vector DNA, transgene mRNA and protein expression in brain and other organs. Compared to untreated Npc2−/− mice, AAV-treated Npc2−/− mice demonstrated amelioration of disease pathology in the brain, reduced lysosomal storage, reduced Purkinje cell death, decreased gliosis, and improved performance in behavioral tasks. Treatment-related reduction in serum disease markers was detected early and this effect persisted. Liver and spleen pathology were improved with significant reduction of liver cholesterol and sphingomyelin levels in treated Npc2−/− mice. Finally, administration of AAVrh.10-mNpc2-HA significantly extended life-span. Taken together, these data demonstrate the benefit of a one-time intracisternal administration of AAVrh.10-mNpc2-HA as a life-long treatment for NPC2 disease.

Original languageEnglish
Pages (from-to)22-33
Number of pages12
JournalExperimental Neurology
Volume306
DOIs
Publication statusPublished - 1 Aug 2018

Fingerprint

Phenotype
Dependovirus
Cholesterol
Pathology
Genes
Gliosis
Sphingomyelins
Purkinje Cells
Liver
Brain
Neurologic Manifestations
Transgenes
Neurodegenerative Diseases
Type C2 Niemann-Pick disease
Liver Diseases
Cell Death
Spleen
Biomarkers
Lipids
Messenger RNA

Keywords

  • AAVrh.10 gene therapy
  • Correction of neurologic and systemic manifestations
  • Intracisternal delivery
  • Niemann pick type C
  • Niemann pick type C2 disease
  • Single administration

ASJC Scopus subject areas

  • Neurology
  • Developmental Neuroscience

Cite this

Attenuation of the Niemann-Pick type C2 disease phenotype by intracisternal administration of an AAVrh.10 vector expressing Npc2. / Markmann, Sandra; J. Christie-Reid, Jasmine; Rosenberg, Jonathan B.; De, Bishnu P.; Kaminsky, Stephen M.; Crystal, Ronald; Sondhi, Dolan.

In: Experimental Neurology, Vol. 306, 01.08.2018, p. 22-33.

Research output: Contribution to journalArticle

Markmann, Sandra ; J. Christie-Reid, Jasmine ; Rosenberg, Jonathan B. ; De, Bishnu P. ; Kaminsky, Stephen M. ; Crystal, Ronald ; Sondhi, Dolan. / Attenuation of the Niemann-Pick type C2 disease phenotype by intracisternal administration of an AAVrh.10 vector expressing Npc2. In: Experimental Neurology. 2018 ; Vol. 306. pp. 22-33.
@article{230a75fd817744e3a6aaeaa21c94d26d,
title = "Attenuation of the Niemann-Pick type C2 disease phenotype by intracisternal administration of an AAVrh.10 vector expressing Npc2",
abstract = "Niemann-Pick type C2 (NPC2) disease is a rare, neurodegenerative disorder caused by mutations in the NPC2 gene, leading to lysosomal accumulation of unesterified cholesterol and other lipids. It is characterized by hepatosplenomegaly, liver dysfunction and severe neurological manifestations, resulting in early death. There is no effective therapy for NPC2 disease. Here, we evaluated the effectiveness of an adeno-associated virus (AAV), serotype rh.10 gene transfer vector expressing the mouse Npc2 gene (AAVrh.10-mNpc2-HA, HA tagged to facilitate analysis) to treat the disease in an Npc2−/− mouse model. A single intracisternal administration of the AAVrh.10-mNpc2-HA to 6 week old Npc2−/− mice mediated vector DNA, transgene mRNA and protein expression in brain and other organs. Compared to untreated Npc2−/− mice, AAV-treated Npc2−/− mice demonstrated amelioration of disease pathology in the brain, reduced lysosomal storage, reduced Purkinje cell death, decreased gliosis, and improved performance in behavioral tasks. Treatment-related reduction in serum disease markers was detected early and this effect persisted. Liver and spleen pathology were improved with significant reduction of liver cholesterol and sphingomyelin levels in treated Npc2−/− mice. Finally, administration of AAVrh.10-mNpc2-HA significantly extended life-span. Taken together, these data demonstrate the benefit of a one-time intracisternal administration of AAVrh.10-mNpc2-HA as a life-long treatment for NPC2 disease.",
keywords = "AAVrh.10 gene therapy, Correction of neurologic and systemic manifestations, Intracisternal delivery, Niemann pick type C, Niemann pick type C2 disease, Single administration",
author = "Sandra Markmann and {J. Christie-Reid}, Jasmine and Rosenberg, {Jonathan B.} and De, {Bishnu P.} and Kaminsky, {Stephen M.} and Ronald Crystal and Dolan Sondhi",
year = "2018",
month = "8",
day = "1",
doi = "10.1016/j.expneurol.2018.04.001",
language = "English",
volume = "306",
pages = "22--33",
journal = "Experimental Neurology",
issn = "0014-4886",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Attenuation of the Niemann-Pick type C2 disease phenotype by intracisternal administration of an AAVrh.10 vector expressing Npc2

AU - Markmann, Sandra

AU - J. Christie-Reid, Jasmine

AU - Rosenberg, Jonathan B.

AU - De, Bishnu P.

AU - Kaminsky, Stephen M.

AU - Crystal, Ronald

AU - Sondhi, Dolan

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Niemann-Pick type C2 (NPC2) disease is a rare, neurodegenerative disorder caused by mutations in the NPC2 gene, leading to lysosomal accumulation of unesterified cholesterol and other lipids. It is characterized by hepatosplenomegaly, liver dysfunction and severe neurological manifestations, resulting in early death. There is no effective therapy for NPC2 disease. Here, we evaluated the effectiveness of an adeno-associated virus (AAV), serotype rh.10 gene transfer vector expressing the mouse Npc2 gene (AAVrh.10-mNpc2-HA, HA tagged to facilitate analysis) to treat the disease in an Npc2−/− mouse model. A single intracisternal administration of the AAVrh.10-mNpc2-HA to 6 week old Npc2−/− mice mediated vector DNA, transgene mRNA and protein expression in brain and other organs. Compared to untreated Npc2−/− mice, AAV-treated Npc2−/− mice demonstrated amelioration of disease pathology in the brain, reduced lysosomal storage, reduced Purkinje cell death, decreased gliosis, and improved performance in behavioral tasks. Treatment-related reduction in serum disease markers was detected early and this effect persisted. Liver and spleen pathology were improved with significant reduction of liver cholesterol and sphingomyelin levels in treated Npc2−/− mice. Finally, administration of AAVrh.10-mNpc2-HA significantly extended life-span. Taken together, these data demonstrate the benefit of a one-time intracisternal administration of AAVrh.10-mNpc2-HA as a life-long treatment for NPC2 disease.

AB - Niemann-Pick type C2 (NPC2) disease is a rare, neurodegenerative disorder caused by mutations in the NPC2 gene, leading to lysosomal accumulation of unesterified cholesterol and other lipids. It is characterized by hepatosplenomegaly, liver dysfunction and severe neurological manifestations, resulting in early death. There is no effective therapy for NPC2 disease. Here, we evaluated the effectiveness of an adeno-associated virus (AAV), serotype rh.10 gene transfer vector expressing the mouse Npc2 gene (AAVrh.10-mNpc2-HA, HA tagged to facilitate analysis) to treat the disease in an Npc2−/− mouse model. A single intracisternal administration of the AAVrh.10-mNpc2-HA to 6 week old Npc2−/− mice mediated vector DNA, transgene mRNA and protein expression in brain and other organs. Compared to untreated Npc2−/− mice, AAV-treated Npc2−/− mice demonstrated amelioration of disease pathology in the brain, reduced lysosomal storage, reduced Purkinje cell death, decreased gliosis, and improved performance in behavioral tasks. Treatment-related reduction in serum disease markers was detected early and this effect persisted. Liver and spleen pathology were improved with significant reduction of liver cholesterol and sphingomyelin levels in treated Npc2−/− mice. Finally, administration of AAVrh.10-mNpc2-HA significantly extended life-span. Taken together, these data demonstrate the benefit of a one-time intracisternal administration of AAVrh.10-mNpc2-HA as a life-long treatment for NPC2 disease.

KW - AAVrh.10 gene therapy

KW - Correction of neurologic and systemic manifestations

KW - Intracisternal delivery

KW - Niemann pick type C

KW - Niemann pick type C2 disease

KW - Single administration

UR - http://www.scopus.com/inward/record.url?scp=85046079678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046079678&partnerID=8YFLogxK

U2 - 10.1016/j.expneurol.2018.04.001

DO - 10.1016/j.expneurol.2018.04.001

M3 - Article

C2 - 29655638

AN - SCOPUS:85046079678

VL - 306

SP - 22

EP - 33

JO - Experimental Neurology

JF - Experimental Neurology

SN - 0014-4886

ER -